Wedbush Increases Earnings Estimates for Avalo Therapeutics

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Stock analysts at Wedbush upped their Q1 2025 earnings estimates for shares of Avalo Therapeutics in a research note issued to investors on Thursday, March 20th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $0.63 for the quarter, up from their prior estimate of $0.55. Wedbush has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share.

A number of other brokerages also recently weighed in on AVTX. BTIG Research started coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective on the stock. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday. Finally, Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $7.66 on Friday. The firm has a 50 day moving average of $7.45 and a 200 day moving average of $9.11. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares during the period. Marshall Wace LLP acquired a new position in Avalo Therapeutics in the 4th quarter worth approximately $114,000. Walleye Capital LLC purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $145,000. Northern Trust Corp acquired a new stake in Avalo Therapeutics during the 4th quarter valued at approximately $168,000. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics in the 4th quarter valued at $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.